2025-522630-31-00RecruitingPhase 1
Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria
Agios Pharmaceuticals Inc.2 sites in 1 country10 target enrollmentStarted: April 29, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Agios Pharmaceuticals Inc.
- Enrollment
- 10
- Locations
- 2
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Scientific Communications
Scientific
Agios Pharmaceuticals Inc.
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
A study in healthy men to test whether BI 1815368 influences the amount of metformin in the body2024-515911-23-00Boehringer Ingelheim International GmbH14
Completed
Phase 1
A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-068214972023-508371-36-00Pfizer Inc.6
Completed
Phase 1
An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)NCT07361354Angitia Incorporated Limited28
Suspended
Phase 1
A study in healthy men to test how BI 1839100 is taken up and handled by the body2024-510870-26-00Boehringer Ingelheim International GmbH16
Recruiting
Phase 1
Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.Treatment of symptomatic anemia associated with chronic renal failure:2025-522246-43-00Blau Farmaceutica S.A.124